APT
has strong financial backing and has recruited a
management team with decades of experience in drug
development, pulmonary and cardiac medicine and commercialization.
"Highly-focused, adaptable
companies such as APT are filling gaps in the drug development
pipeline. APT's expertise and willingness to take on
orphaned drugs can bring tremendous benefits to patients
who might not otherwise receive treatment."
Daniel Ruppar
Pharmaceuticals & Biotechnology Industry
Manager
(North America), Frost & Sullivan
